Get the Stockscreener App
27.54
2.53%
0.68
Pre-market:
27.66
0.12
+0.44%
Moderna Inc stock is traded at $27.54, with a volume of 9.86M.
It is up +2.53% in the last 24 hours and up +4.87% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$26.86
Open:
$27.05
24h Volume:
9.86M
Relative Volume:
0.94
Market Cap:
$10.71B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.1546
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+8.43%
1M Performance:
+4.87%
6M Performance:
-31.88%
1Y Performance:
-77.51%
1-Day Range:
$26.80
$28.24
1-Week Range:
$25.16
$28.24
52-Week Range:
$23.15
$129.39
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
27.54 | 10.71B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
BDF Gestion Invests $783,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna’s SWOT analysis: mRNA pioneer’s stock faces pivotal moment - Investing.com
Trump administration cancels Moderna contract to fight bird flu and other viruses - Arizona Daily Star
Moderna (MRNA) Sees Bullish Trading Activity with Increased Options Volume | MRNA Stock News - GuruFocus
US Senate Democrats demand Kennedy explain canceling bird flu vaccine contract - MarketScreener
Zika Virus Therapeutics Market Size & Share | Industry Growth [2032] - SkyQuest Technology
AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine - Benzinga
Moderna (MRNA) Sees Bearish Sentiment Among Option Traders | MRNA Stock News - GuruFocus
Insurers likely to cover vaccines without ACIP recommendations - Seeking Alpha
SG Americas Securities LLC Lowers Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Rakuten Securities Inc. Has $742,000 Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Robert F. Kennedy Jr.'s CDC Overhaul 'Critically Weakened' US Vaccine Program, Say Ousted Experts - Benzinga
Moderna Target of Unusually High Options Trading (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Stock Price Down 3.8%Here's What Happened - MarketBeat
Transcript : Moderna, Inc.Special Call - MarketScreener
Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Tobam - MarketBeat
Union Bancaire Privee UBP SA Reduces Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna | History, Innovation, Challenges, & Facts - Britannica
FDA approves Moderna’s new COVID-19 vaccine - Santa Clarita Valley Signal
FDA approves expanded use of Moderna’s RSV shot - MSN
Moderna, Inc. (MRNA) stock price, news, quote and history - Yahoo
GAMMA Investing LLC Grows Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna’s SWOT analysis: mrna stock faces challenges amid vaccine shifts - Investing.com
Here's Why Moderna (MRNA) Fell More Than Broader Market - sharewise
Moderna Seeks Outside Investors to Fund Select Vaccine Trials - MSN
FDA expands approval of Moderna’s RSV vaccine to some adults under age 60 - weisradio.com
FDA expands approval of Moderna's RSV vaccine to some adults under age 60 - WBAL News Radio
FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains - The Hill
IBM and Moderna tout use cases for AI in total rewards - HR Brew
Moderna falls on doubts over new CDC panel's backing of RSV vaccine - Reuters
Moderna (MRNA) Faces Challenges Despite RSV Vaccine Approval - GuruFocus
Moderna wins FDA OK to widen use of RSV vaccine - BioPharma Dive
Moderna Stock Falls on CDC Panel Concerns Over RSV VaccineNews and Statistics - IndexBox
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59 - The Boston Globe
Moderna under pressure despite RSV vaccine approval into wider age group - MSN
FDA nod for Moderna’s RSV Vaccine, mRESVIA for younger adults - The Pharma Letter
Moderna (MRNA) Faces Intensified Short Selling Amid Challenges - GuruFocus
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects - TradingView
Moderna Wins Expanded Label for mRNA RSV Shot as New ACIP Members Question mRNA Technology - BioSpace
Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults - Yahoo Finance
Moderna's RSV shot gets US nod for use in younger adults - pharmaphorum
Moderna (MRNA) Gains FDA Approval for Expanded RSV Vaccine Use - GuruFocus
FDA expands Moderna's RSV vaccine approval to at-risk adults (MRNA:NASDAQ) - Seeking Alpha
FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up - Benzinga
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease - Knoxville News Sentinel
Moderna Gets FDA Approval for mRESVIA in Adults Aged 18-59 at Increased Risk for RSV Disease - marketscreener.com
Moderna (MRNA) Receives FDA Nod for RSV Vaccine Extended Use | M - GuruFocus
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):